<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>VESICARE- solifenacin succinate tablet, film coated </strong><br>Cardinal Health<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use VESIcare<span class="Sup">®</span> safely and effectively. See full prescribing information for VESIcare.<br><br>VESIcare (solifenacin succinate) tablets<br>Initial U.S. Approval: 2004</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div><p class="Highlighta">VESIcare is a muscarinic antagonist indicated for the treatment of <span class="product-label-link" type="condition" conceptid="76153" conceptname="Low compliance bladder">overactive bladder</span> with symptoms of urge <span class="product-label-link" type="condition" conceptid="197672" conceptname="Urinary incontinence">urinary incontinence</span>, urgency, and <span class="product-label-link" type="condition" conceptid="4012368" conceptname="Increased frequency of urination">urinary frequency</span> (<a href="#i4i_indications_id_e80f8203-0722-4e16-ac04-d6b03e17047f">1</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><dl>
<dt>•</dt>
<dd>5 mg tablet taken once daily, and if well tolerated may be increased to 10 mg once daily (<a href="#i4i_section_id_1e9aca86-8008-4d7a-a5cc-75f2054c0187">2.1</a>)</dd>
<dt>•</dt>
<dd>Do not exceed 5 mg tablet once daily in patients with:<dl>
<dt>•</dt>
<dd>severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> [Creatinine Clearance] (CL<span class="Sub">cr</span> &lt;30 ml/min) (<a href="#i4i_section_id_1e9aca86-8008-4d7a-a5cc-75f2054c0187">2.2</a>) </dd>
<dt>•</dt>
<dd>moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (Child-Pugh B) (<a href="#i4i_section_id_23bb397a-732b-4191-96c4-1dcf2c8299e7">2.3</a>)</dd>
<dt>•</dt>
<dd>concomitant use of potent CYP3A4 inhibitors (<a href="#i4i_section_id_9fb6f61b-bddf-4919-95d2-eb71856fa4f9">2.4</a>)</dd>
</dl>
</dd>
<dt>•</dt>
<dd>Use of VESIcare is not recommended in patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (Child-Pugh C) (<a href="#i4i_section_id_23bb397a-732b-4191-96c4-1dcf2c8299e7">2.3</a>)</dd>
</dl></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">Tablets: 5 mg and 10 mg (<a href="#i4i_dosage_form_strength_id_5c694ec3-c8b9-4875-9526-379bb64c7a70">3</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><dl>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">Urinary retention</span> (<a href="#i4i_contraindications_id_5b3294b0-c727-445c-bbdd-9fb018b8b088">4</a>, <a href="#i4i_section_id_12616c3c-35b3-4d2b-97f1-4c9fdb7b5bdb">5.2</a>)</dd>
<dt>•</dt>
<dd>Gastric retention (<a href="#i4i_contraindications_id_5b3294b0-c727-445c-bbdd-9fb018b8b088">4</a>, <a href="#i4i_section_id_a130c1fd-6a98-48c8-92e4-622eca13517c">5.3</a>)</dd>
<dt>•</dt>
<dd>Uncontrolled narrow-angle <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span> (<a href="#i4i_contraindications_id_5b3294b0-c727-445c-bbdd-9fb018b8b088">4</a>, <a href="#i4i_section_id_87ba0277-c99b-4c2c-8634-510b3d0b51e2">5.5</a>)</dd>
<dt>•</dt>
<dd>In patients who have demonstrated <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to the drug (<a href="#i4i_contraindications_id_5b3294b0-c727-445c-bbdd-9fb018b8b088">4</a>, <a href="#i4i_section_id_b62deebf-e42c-46e7-aa73-7da3d2911e2d">6.2</a>)</dd>
</dl></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><dl>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">Angioedema</span> and <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reactions</span>: Reports of <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> of the face, lips and/or larynx, in some cases occurring after the first dose, have been described. <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylactic reactions</span> have been reported rarely (<a href="#i4i_warnings_precautions_duplicate_id_c9e398b5-405c-413d-a035-941b7285f33c">5.1</a>)</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">Urinary Retention</span>: Administer with caution to patients with clinically significant bladder outflow obstruction (<a href="#i4i_section_id_12616c3c-35b3-4d2b-97f1-4c9fdb7b5bdb">5.2</a>)</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal Disorders</span>: Use with caution in patients with decreased gastrointestinal motility (<a href="#i4i_section_id_a130c1fd-6a98-48c8-92e4-622eca13517c">5.3</a>)</dd>
<dt>•</dt>
<dd>Central Nervous System Effects: <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span> has been reported with VESIcare. Advise patients not to drive or operate heavy machinery until they know how VESIcare affects them (<a href="#i4i_warnings_precautions_duplicate_id_c9e398b5-405c-413d-a035-941b7285f33c">5.4</a>)</dd>
<dt>•</dt>
<dd>Controlled Narrow-Angle <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">Glaucoma</span>: Use with caution in patients being treated for narrow-angle <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span> (<a href="#i4i_section_id_87ba0277-c99b-4c2c-8634-510b3d0b51e2">5.5</a>)</dd>
<dt>•</dt>
<dd>QT Prolongation: Use with caution in patients with a known history of QT prolongation or patients who are taking medications known to prolong the QT interval (<a href="#i4i_section_id_2b5a5b7e-380f-4cc8-86b2-83406f82e4f7">5.8</a>)</dd>
</dl></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div><p class="Highlighta"><span class="Bold">The most common adverse reactions (&gt; 4% and &gt; placebo) were <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, and <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> at both 5 mg and 10 mg doses; and <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infection</span>, and <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span> at the 10 mg dose (</span><a href="#i4i_section_id_b58c14d1-b2cb-4d12-89b2-e73ef0fcf35f">6.1</a><span class="Bold">)To report SUSPECTED ADVERSE REACTIONS, contact Astellas Pharma US, Inc at 1-800-727-7003 or FDA at 1-800-FDA-1088 or <a href="http://www.fda.gov/medwatch">http://www.fda.gov/medwatch</a>.</span> </p></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><dl>
<dt>•</dt>
<dd>Inhibitors of CYP3A4 may increase the concentration of VESIcare. (<a href="#i4i_section_id_f85b52ec-6611-4cd9-9b51-729288ed8e1b">7.1</a>)</dd>
<dt>•</dt>
<dd>Inducers of CYP3A4 may decrease the concentration of VESIcare. (<a href="#i4i_drug_interaction_id_914d7074-3dd4-43bd-81b4-33fd3ac91e3f">7.2</a>)</dd>
</dl></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div>
<p class="Highlighta"><span class="Italics">Pregnancy and Nursing Mothers</span>: VESIcare should be used during pregnancy only if the potential benefit for the mother justifies the potential risk to the fetus. VESIcare should not be administered during nursing (<a href="#i4i_pregnancy_id_ab3c76c6-93c1-45ae-90d8-94d678b0e26d">8.1</a>, <a href="#i4i_nursing_mothers_id_eac811c6-2ad3-417d-8e41-5c77ecd086a0">8.3</a>) </p>
<p class="Highlighta"><span class="Italics">Pediatric Use</span>: The safety and effectiveness of VESIcare in pediatric patients have not been established (<a href="#i4i_pediatric_use_id_4a4c58b7-b985-4bdf-8b98-3792ceb912f0">8.4</a>)<br><br> </p>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.</p>
<p class="HighlightsRevision">Revised: 9/2015</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1 Dosing Information</a></h2>
<h2><a href="#section-2.2" class="toc">2.2 Dose Adjustment in Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h2><a href="#section-2.3" class="toc">2.3 Dose Adjustment in Patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></a></h2>
<h2><a href="#section-2.4" class="toc">2.4 Dose Adjustment in Patients Taking CYP3A4 Inhibitors</a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc"> 5.1 <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">Angioedema</span> and <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylactic Reactions</span> </a></h2>
<h2><a href="#section-5.2" class="toc">5.2 <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">Urinary Retention</span></a></h2>
<h2><a href="#section-5.3" class="toc">5.3 <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal Disorders</span></a></h2>
<h2><a href="#section-5.4" class="toc">5.4 Central Nervous System Effects</a></h2>
<h2><a href="#section-5.5" class="toc">5.5 Controlled Narrow-Angle <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">Glaucoma</span></a></h2>
<h2><a href="#section-5.6" class="toc">5.6 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></a></h2>
<h2><a href="#section-5.7" class="toc">5.7 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h2><a href="#section-5.8" class="toc">5.8 Patients with Congenital or Acquired QT Prolongation</a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Trials Experience</a></h2>
<h2><a href="#section-6.2" class="toc">6.2 Post-Marketing Experience</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">7.1 Potent CYP3A4 Inhibitors</a></h2>
<h2><a href="#section-7.2" class="toc">7.2 CYP3A4 Inducers</a></h2>
<h2><a href="#section-7.3" class="toc">7.3 Drugs Metabolized by Cytochrome P450</a></h2>
<h2><a href="#section-7.4" class="toc">7.4 Warfarin</a></h2>
<h2><a href="#section-7.5" class="toc">7.5 Oral Contraceptives</a></h2>
<h2><a href="#section-7.6" class="toc">7.6 Digoxin</a></h2>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.2 Labor and Delivery</a></h2>
<h2><a href="#section-8.3" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.4" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.5 Geriatric Use</a></h2>
<h2><a href="#section-8.6" class="toc">8.6 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h2><a href="#section-8.7" class="toc">8.7 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></a></h2>
<h2><a href="#section-8.8" class="toc">8.8 Gender</a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.2 Pharmacodynamics</a></h2>
<h2><a href="#section-11.3" class="toc">12.3 Pharmacokinetics</a></h2>
<h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-13" class="toc">14 CLINICAL STUDIES</a></h1>
<h1><a href="#section-14" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-15" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_e80f8203-0722-4e16-ac04-d6b03e17047f"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<p class="First">VESIcare is a muscarinic antagonist indicated for the treatment of <span class="product-label-link" type="condition" conceptid="76153" conceptname="Low compliance bladder">overactive bladder</span> with symptoms of urge <span class="product-label-link" type="condition" conceptid="197672" conceptname="Urinary incontinence">urinary incontinence</span>, urgency, and <span class="product-label-link" type="condition" conceptid="4012368" conceptname="Increased frequency of urination">urinary frequency</span>.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_643a9c2b-c263-44a3-b089-4ebe12978806"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_1e9aca86-8008-4d7a-a5cc-75f2054c0187"></a><a name="section-2.1"></a><p></p>
<h2>2.1 Dosing Information</h2>
<p class="First">The recommended dose of VESIcare is 5 mg once daily. If the 5 mg dose is well tolerated, the dose may be increased to 10 mg once daily.</p>
<p>VESIcare should be taken with water and swallowed whole. VESIcare can be administered with or without food.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_23bb397a-732b-4191-96c4-1dcf2c8299e7"></a><a name="section-2.2"></a><p></p>
<h2>2.2 Dose Adjustment in Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First">For patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (CL<span class="Sub">cr</span> &lt;30 mL/min), a daily dose of VESIcare greater than 5 mg is not recommended [<span class="Italics">see <a href="#i4i_section_id_d44eeb38-983b-466a-87e6-1e4533058857">Warnings and Precautions</a> (<a href="#i4i_section_id_d44eeb38-983b-466a-87e6-1e4533058857">5.7</a>); <a href="#i4i_section_id_19f5df28-2ad0-43d4-bd3b-4c4ae29fc17c">Use in Specific Populations</a> (<a href="#i4i_section_id_19f5df28-2ad0-43d4-bd3b-4c4ae29fc17c">8.6</a>)</span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_dosage_admin_duplicate_id_728ae196-b8f7-4d34-a921-87f546f1d41c"></a><a name="section-2.3"></a><p></p>
<h2>2.3 Dose Adjustment in Patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<p class="First">For patients with moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (Child-Pugh B), a daily dose of VESIcare greater than 5 mg is not recommended. Use of VESIcare in patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (Child-Pugh C) is not recommended [<span class="Italics">see <a href="#i4i_section_id_f5f8e5ea-2387-4f2d-8880-5bfddd0f2e24">Warnings and Precautions</a> (<a href="#i4i_section_id_f5f8e5ea-2387-4f2d-8880-5bfddd0f2e24">5.6</a>); <a href="#i4i_section_id_1aedf6cf-afc3-456f-91b0-61d49a9929a2">Use in Specific Populations</a> (<a href="#i4i_section_id_1aedf6cf-afc3-456f-91b0-61d49a9929a2">8.7</a>)</span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_9fb6f61b-bddf-4919-95d2-eb71856fa4f9"></a><a name="section-2.4"></a><p></p>
<h2>2.4 Dose Adjustment in Patients Taking CYP3A4 Inhibitors</h2>
<p class="First">When administered with potent CYP3A4 inhibitors such as ketoconazole, a daily dose of VESIcare greater than 5 mg is not recommended [<span class="Italics">see <a href="#i4i_section_id_f85b52ec-6611-4cd9-9b51-729288ed8e1b">Drug Interactions</a> (<a href="#i4i_section_id_f85b52ec-6611-4cd9-9b51-729288ed8e1b">7.1</a>)</span>].</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="i4i_dosage_form_strength_id_5c694ec3-c8b9-4875-9526-379bb64c7a70"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">The 5 mg tablets are round, light yellow, debossed with 150.</p>
<p>The 10 mg tablets are round, light pink, debossed with 151.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_5b3294b0-c727-445c-bbdd-9fb018b8b088"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<p class="First">VESIcare is contraindicated in patients with:</p>
<dl>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">urinary retention</span> [<span class="Italics">see <a href="#i4i_section_id_12616c3c-35b3-4d2b-97f1-4c9fdb7b5bdb">Warnings and Precautions</a> (<a href="#i4i_section_id_12616c3c-35b3-4d2b-97f1-4c9fdb7b5bdb">5.2</a>)</span>],</dd>
<dt>•</dt>
<dd>gastric retention [<span class="Italics">see <a href="#i4i_section_id_a130c1fd-6a98-48c8-92e4-622eca13517c">Warnings and Precautions</a> (<a href="#i4i_section_id_a130c1fd-6a98-48c8-92e4-622eca13517c">5.3</a>)</span>],</dd>
<dt>•</dt>
<dd>uncontrolled narrow-angle <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span> [<span class="Italics">see <a href="#i4i_section_id_87ba0277-c99b-4c2c-8634-510b3d0b51e2">Warnings and Precautions</a> (<a href="#i4i_section_id_87ba0277-c99b-4c2c-8634-510b3d0b51e2">5.5</a>)</span>], and</dd>
<dt>•</dt>
<dd>in patients who have demonstrated <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to the drug [<span class="Italics">see <a href="#i4i_section_id_b62deebf-e42c-46e7-aa73-7da3d2911e2d">Adverse Reactions</a> (<a href="#i4i_section_id_b62deebf-e42c-46e7-aa73-7da3d2911e2d">6.2</a>)</span>].</dd>
</dl>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="i4i_warnings_precautions_id_c7a8b09d-ba8e-4778-86e0-66da62690778"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_warnings_precautions_duplicate_id_e31df573-8a96-409f-bb9f-ec384885f970"></a><a name="section-5.1"></a><p></p>
<h2> 5.1 <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">Angioedema</span> and <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylactic Reactions</span> </h2>
<p class="First"> <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">Angioedema</span> of the face, lips, tongue, and/or larynx have been reported with solifenacin. In some cases <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> occurred after the first dose. Cases of <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> have been reported to occur hours after the first dose or after multiple doses. <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">Angioedema</span> associated with upper airway <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> may be life threatening. If involvement of the tongue, hypopharynx, or larynx occurs, solifenacin should be promptly discontinued and appropriate therapy and/or measures necessary to ensure a patent airway should be promptly provided.  <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylactic reactions</span> have been reported rarely in patients treated with solifenacin succinate. Solifenacin succinate should not be used in patients with a known or suspected <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to solifenacin succinate. In patients who develop <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reactions</span>, solifenacin succinate should be discontinued and appropriate therapy and/or measures should be taken. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_12616c3c-35b3-4d2b-97f1-4c9fdb7b5bdb"></a><a name="section-5.2"></a><p></p>
<h2>5.2 <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">Urinary Retention</span></h2>
<p class="First">VESIcare, like other anticholinergic drugs, should be administered with caution to patients with clinically significant bladder outflow obstruction because of the risk of <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">urinary retention</span> [<span class="Italics">see <a href="#i4i_contraindications_id_5b3294b0-c727-445c-bbdd-9fb018b8b088">Contraindications</a> (<a href="#i4i_contraindications_id_5b3294b0-c727-445c-bbdd-9fb018b8b088">4</a>)</span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_a130c1fd-6a98-48c8-92e4-622eca13517c"></a><a name="section-5.3"></a><p></p>
<h2>5.3 <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal Disorders</span></h2>
<p class="First">VESIcare, like other anticholinergics, should be used with caution in patients with decreased gastrointestinal motility [<span class="Italics">see <a href="#i4i_contraindications_id_5b3294b0-c727-445c-bbdd-9fb018b8b088">Contraindications</a> (<a href="#i4i_contraindications_id_5b3294b0-c727-445c-bbdd-9fb018b8b088">4</a>)</span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_warnings_precautions_duplicate_id_c9e398b5-405c-413d-a035-941b7285f33c"></a><a name="section-5.4"></a><p></p>
<h2>5.4 Central Nervous System Effects</h2>
<p class="First">VESIcare is associated with anticholinergic central nervous system (CNS) effects [<span class="Italics">see <a href="#i4i_adverse_effects_id_27bd8e59-078f-4dc1-8656-fc74665a4c16">Adverse Reactions</a> (<a href="#i4i_section_id_b62deebf-e42c-46e7-aa73-7da3d2911e2d">6.2</a>)</span>]. A variety of CNS anticholinergic effects have been reported, including <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span> and <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>. Patients should be monitored for signs of anticholinergic CNS effects, particularly after beginning treatment or increasing the dose. Advise patients not to drive or operate heavy machinery until they know how VESIcare affects them. If a patient experiences anticholinergic CNS effects, dose reduction or drug discontinuation should be considered.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_87ba0277-c99b-4c2c-8634-510b3d0b51e2"></a><a name="section-5.5"></a><p></p>
<h2>5.5 Controlled Narrow-Angle <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">Glaucoma</span></h2>
<p class="First">VESIcare should be used with caution in patients being treated for narrow-angle <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span> [<span class="Italics">see <a href="#i4i_contraindications_id_5b3294b0-c727-445c-bbdd-9fb018b8b088">Contraindications</a> (<a href="#i4i_contraindications_id_5b3294b0-c727-445c-bbdd-9fb018b8b088">4</a>)</span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_f5f8e5ea-2387-4f2d-8880-5bfddd0f2e24"></a><a name="section-5.6"></a><p></p>
<h2>5.6 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<p class="First">VESIcare should be used with caution in patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. Doses of VESIcare greater than 5 mg are not recommended in patients with moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (Child-Pugh B). VESIcare is not recommended for patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (Child-Pugh C) [<span class="Italics">see <a href="#i4i_section_id_23bb397a-732b-4191-96c4-1dcf2c8299e7">Dosage and Administration</a> (<a href="#i4i_dosage_admin_duplicate_id_728ae196-b8f7-4d34-a921-87f546f1d41c">2.3</a>) and <a href="#i4i_section_id_19f5df28-2ad0-43d4-bd3b-4c4ae29fc17c">Use in Specific Populations</a> (<a href="#i4i_section_id_1aedf6cf-afc3-456f-91b0-61d49a9929a2">8.7</a>)</span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_d44eeb38-983b-466a-87e6-1e4533058857"></a><a name="section-5.7"></a><p></p>
<h2>5.7 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First">VESIcare should be used with caution in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. Doses of VESIcare greater than 5 mg are not recommended in patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (CL<span class="Sub">cr</span> &lt;30 mL/min) [<span class="Italics">see <a href="#i4i_section_id_23bb397a-732b-4191-96c4-1dcf2c8299e7">Dosage and Administration</a> (<a href="#i4i_section_id_23bb397a-732b-4191-96c4-1dcf2c8299e7">2.2</a>) and <a href="#i4i_section_id_1aedf6cf-afc3-456f-91b0-61d49a9929a2">Use in Specific Populations</a> (<a href="#i4i_section_id_19f5df28-2ad0-43d4-bd3b-4c4ae29fc17c">8.6</a>)</span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_2b5a5b7e-380f-4cc8-86b2-83406f82e4f7"></a><a name="section-5.8"></a><p></p>
<h2>5.8 Patients with Congenital or Acquired QT Prolongation</h2>
<p class="First">In a study of the effect of solifenacin on the QT interval in 76 healthy women [<span class="Italics">see <a href="#i4i_pharmacodynamics_id_a3f06821-84cd-476d-b6e7-69d954d7f054">Clinical Pharmacology</a> (<a href="#i4i_pharmacodynamics_id_a3f06821-84cd-476d-b6e7-69d954d7f054">12.2</a>)</span>] the QT prolonging effect appeared less with solifenacin 10 mg than with 30 mg (three times the maximum recommended dose), and the effect of solifenacin 30 mg did not appear as large as that of the positive control moxifloxacin at its therapeutic dose. This observation should be considered in clinical decisions to prescribe VESIcare for patients with a known history of QT prolongation or patients who are taking medications known to prolong the QT interval.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_27bd8e59-078f-4dc1-8656-fc74665a4c16"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_b58c14d1-b2cb-4d12-89b2-e73ef0fcf35f"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Trials Experience</h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</p>
<p>VESIcare has been evaluated for safety in 1811 patients in randomized, placebo-controlled trials. Expected adverse reactions of antimuscarinic agents are <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span> (accommodation abnormalities), <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">urinary retention</span>, and <span class="product-label-link" type="condition" conceptid="373204" conceptname="Conjunctival xerosis">dry eyes</span>. The incidence of <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span> and <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> in patients treated with VESIcare was higher in the 10 mg compared to the 5 mg dose group. </p>
<p>In the four 12-week double-blind clinical trials, severe <span class="product-label-link" type="condition" conceptid="4258683" conceptname="Fecal impaction">fecal impaction</span>, <span class="product-label-link" type="condition" conceptid="4090128" conceptname="Large bowel obstruction">colonic obstruction</span>, and <span class="product-label-link" type="condition" conceptid="193518" conceptname="Intestinal obstruction">intestinal obstruction</span> were reported in one patient each, all in the VESIcare 10 mg group. <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">Angioneurotic edema</span> has been reported in one patient taking VESIcare 5 mg. Compared to 12 weeks of treatment with VESIcare, the incidence and severity of adverse reactions were similar in patients who remained on drug for up to 12 months. </p>
<p>The most frequent adverse reaction leading to study discontinuation was <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span> (1.5%). <a href="#_Ref369255821">Table 1</a> lists the rates of identified adverse reactions, derived from all reported adverse events, in randomized, placebo-controlled trials at an incidence greater than placebo and in 1% or more of patients treated with VESIcare 5 or 10 mg once daily for up to 12 weeks.</p>
<a name="_Ref369255821"></a><table width="100%">
<caption><span>Table 1. Percentages of Patients with Identified Adverse Reactions, Derived from All Adverse Events Exceeding Placebo Rate and Reported by 1% or More Patients for Combined Pivotal Studies</span></caption>
<col width="64%">
<col width="13%">
<col width="12%">
<col width="12%">
<thead><tr class="First Last">
<th class="Botrule Lrule Rrule Toprule" align="left" valign="top"></th>
<th class="Botrule Rrule Toprule" align="left" valign="top">
<span class="Bold">Placebo</span><br><span class="Bold">(%)</span>
</th>
<th class="Botrule Rrule Toprule" align="left" valign="top">
<span class="Bold">VESIcare</span><br><span class="Bold">5 mg</span><br><span class="Bold">(%)</span>
</th>
<th class="Botrule Rrule Toprule" align="left" valign="top">
<span class="Bold">VESIcare</span><br><span class="Bold">10 mg</span><br><span class="Bold">(%)</span>
</th>
</tr></thead>
<tbody>
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="Bold">Number of Patients</span></p></td>
<td class="Botrule Rrule Toprule" align="center" valign="middle"><p class="First"><span class="Bold">1216</span></p></td>
<td class="Botrule Rrule Toprule" align="center" valign="middle"><p class="First"><span class="Bold">578</span></p></td>
<td class="Botrule Rrule Toprule" align="center" valign="middle"><p class="First"><span class="Bold">1233</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">GASTROINTESTINAL DISORDERS</span></span></p></td>
<td class="Botrule Rrule" valign="middle"></td>
<td class="Botrule Rrule" valign="middle"></td>
<td class="Botrule Rrule" valign="middle"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">     <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">Dry Mouth</span></p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">4.2</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">10.9</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">27.6</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">     <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span></p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">2.9</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">5.4</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">13.4</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">     <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">2.0</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">1.7</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">3.3</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">     <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span></p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">1.0</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">1.4</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">3.9</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">     <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">Abdominal Pain Upper</span></p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">1.0</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">1.9</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">1.2</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">     <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span> NOS</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">0.9</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">0.2</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">1.1</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">INFECTIONS</span> AND <span class="product-label-link" type="condition" conceptid="432251" conceptname="Disease caused by parasite">INFESTATIONS</span></span></p></td>
<td class="Botrule Rrule" valign="middle"></td>
<td class="Botrule Rrule" valign="middle"></td>
<td class="Botrule Rrule" valign="middle"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">     <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">Urinary Tract Infection</span> NOS</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">2.8</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">2.8</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">4.8</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">     <span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">Influenza</span></p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">1.3</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">2.2</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">0.9</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">     <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">Pharyngitis</span> NOS</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">1.0</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">0.3</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">1.1</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">NERVOUS SYSTEM DISORDERS</span></span></p></td>
<td class="Botrule Rrule" valign="middle"></td>
<td class="Botrule Rrule" valign="middle"></td>
<td class="Botrule Rrule" valign="middle"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">     <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">1.8</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">1.9</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">1.8</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="375252" conceptname="Disorder of eye">EYE DISORDERS</span></span></p></td>
<td class="Botrule Rrule" valign="middle"></td>
<td class="Botrule Rrule" valign="middle"></td>
<td class="Botrule Rrule" valign="middle"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">     <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">Vision Blurred</span></p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">1.8</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">3.8</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">4.8</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">     <span class="product-label-link" type="condition" conceptid="373204" conceptname="Conjunctival xerosis">Dry Eyes</span> NOS</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">0.6</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">0.3</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">1.6</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="Bold">RENAL AND URINARY DISORDERS</span></p></td>
<td class="Botrule Rrule" valign="middle"></td>
<td class="Botrule Rrule" valign="middle"></td>
<td class="Botrule Rrule" valign="middle"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">     <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">Urinary Retention</span></p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">0.6</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">0</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">1.4</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="Bold">GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS</span></p></td>
<td class="Botrule Rrule" valign="middle"></td>
<td class="Botrule Rrule" valign="middle"></td>
<td class="Botrule Rrule" valign="middle"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">     <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">Edema Lower Limb</span></p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">0.7</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">0.3</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">1.1</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">     <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span></p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">1.1</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">1.0</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">2.1</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="Bold">PSYCHIATRIC DISORDERS</span></p></td>
<td class="Botrule Rrule" valign="middle"></td>
<td class="Botrule Rrule" valign="middle"></td>
<td class="Botrule Rrule" valign="middle"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">     <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span> NOS</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">0.8</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">1.2</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">0.8</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="Bold">RESPIRATORY, THORACIC AND <span class="product-label-link" type="condition" conceptid="440142" conceptname="Disorder of mediastinum">MEDIASTINAL DISORDERS</span></span></p></td>
<td class="Botrule Rrule" valign="middle"></td>
<td class="Botrule Rrule" valign="middle"></td>
<td class="Botrule Rrule" valign="middle"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">    <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Cough</span></p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">0.2</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">0.2</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">1.1</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="443784" conceptname="Vascular disorder">VASCULAR DISORDERS</span></span></p></td>
<td class="Botrule Rrule" valign="middle"></td>
<td class="Botrule Rrule" valign="middle"></td>
<td class="Botrule Rrule" valign="middle"></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" valign="top"><p class="First">    <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span> NOS</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">0.6</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">1.4</p></td>
<td class="Botrule Rrule" align="center" valign="middle"><p class="First">0.5</p></td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_b62deebf-e42c-46e7-aa73-7da3d2911e2d"></a><a name="section-6.2"></a><p></p>
<h2>6.2 Post-Marketing Experience</h2>
<p class="First">Because these spontaneously reported events are from the worldwide postmarketing experience, the frequency of events and the role of solifenacin in their causation cannot be reliably determined.</p>
<p>The following events have been reported in association with solifenacin use in worldwide postmarketing experience: </p>
<p><span class="Italics"><span class="Underline">General</span></span>: <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">peripheral edema</span>, <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span>, including <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span> with airway obstruction, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, and <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reaction</span>; </p>
<p><span class="Italics"><span class="Underline">Central Nervous</span></span>: <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>, <span class="product-label-link" type="condition" conceptid="373995" conceptname="Delirium">delirium</span> and <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>; </p>
<p><span class="Italics"><span class="Underline">Cardiovascular</span></span>: QT prolongation; <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">Torsade de Pointes</span>, <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">atrial fibrillation</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitations</span>;</p>
<p><span class="Italics"><span class="Underline">Hepatic</span></span>: <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">liver disorders</span> mostly characterized by <span class="product-label-link" type="condition" conceptid="438878" conceptname="Liver function tests abnormal">abnormal liver function tests</span>, AST (<span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">aspartate aminotransferase</span>), ALT (<span class="product-label-link" type="condition" conceptid="4211515" conceptname="Alanine aminotransferase">alanine aminotransferase</span>), GGT (gamma-glutamyl transferase);</p>
<p><span class="Italics"><span class="Underline">Renal</span></span>: <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>;</p>
<p><span class="Italics"><span class="Underline">Metabolism and nutrition disorders</span></span>: <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">decreased appetite</span>, <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span>;</p>
<p><span class="Italics"><span class="Underline">Dermatologic</span></span>: <span class="product-label-link" type="condition" conceptid="4270887" conceptname="Erythroderma">exfoliative dermatitis</span> and <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span>;</p>
<p><span class="Italics"><span class="Underline"><span class="product-label-link" type="condition" conceptid="375252" conceptname="Disorder of eye">Eye disorders</span></span>:</span><span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>;</p>
<p><span class="Italics"><span class="Underline"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal disorders</span></span>:</span><span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">gastroesophageal reflux disease</span> and <span class="product-label-link" type="condition" conceptid="193518" conceptname="Intestinal obstruction">ileus</span>;</p>
<p><span class="Italics"><span class="Underline">Respiratory, thoracic and <span class="product-label-link" type="condition" conceptid="440142" conceptname="Disorder of mediastinum">mediastinal disorders</span></span>:</span> <span class="product-label-link" type="condition" conceptid="432730" conceptname="Difficulty speaking">dysphonia</span>;</p>
<p><span class="Italics"><span class="Underline">Musculoskeletal and <span class="product-label-link" type="condition" conceptid="253549" conceptname="Disorder of connective tissue">connective tissue disorders</span></span>:</span> <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscular weakness</span>;</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="i4i_interactions_id_c12fd4d5-60cd-4ebc-b565-fca4c81ecbcb"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_f85b52ec-6611-4cd9-9b51-729288ed8e1b"></a><a name="section-7.1"></a><p></p>
<h2>7.1 Potent CYP3A4 Inhibitors</h2>
<p class="First">Following the administration of 10 mg of VESIcare in the presence of 400 mg of ketoconazole, a potent inhibitor of CYP3A4, the mean C<span class="Sub">max</span> and AUC of solifenacin increased by 1.5 and 2.7-fold, respectively. Therefore, it is recommended not to exceed a 5 mg daily dose of VESIcare when administered with therapeutic doses of ketoconazole or other potent CYP3A4 inhibitors [<span class="Italics">see <a href="#i4i_section_id_9fb6f61b-bddf-4919-95d2-eb71856fa4f9">Dosage and Administration</a> (<a href="#i4i_section_id_9fb6f61b-bddf-4919-95d2-eb71856fa4f9">2.4</a>) and <a href="#i4i_pharmacokinetics_id_e65529dc-1dcb-4acd-8121-fafca9daaf03">Clinical Pharmacology</a> (<a href="#i4i_pharmacokinetics_id_e65529dc-1dcb-4acd-8121-fafca9daaf03">12.3</a>)</span>]. The effects of weak or moderate CYP3A4 inhibitors were not examined.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_drug_interaction_id_914d7074-3dd4-43bd-81b4-33fd3ac91e3f"></a><a name="section-7.2"></a><p></p>
<h2>7.2 CYP3A4 Inducers</h2>
<p class="First">There were no <span class="Italics">in vivo</span> studies conducted to evaluate the effect of CYP3A4 inducers on VESIcare. <span class="Italics">In vitro</span> drug metabolism studies have shown that solifenacin is a substrate of CYP3A4. Therefore, inducers of CYP3A4 may decrease the concentration of solifenacin.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_6e395993-efe4-4fb6-a5c2-8378dba8ad37"></a><a name="section-7.3"></a><p></p>
<h2>7.3 Drugs Metabolized by Cytochrome P450</h2>
<p class="First">At therapeutic concentrations, solifenacin does not inhibit CYP1A1/2, 2C9, 2C19, 2D6, or 3A4 derived from human liver microsomes.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_4299cfa7-ecb5-4e51-b8e0-f4bae31d2829"></a><a name="section-7.4"></a><p></p>
<h2>7.4 Warfarin</h2>
<p class="First">Solifenacin has no significant effect on the pharmacokinetics of <span class="Italics">R</span>-warfarin or <span class="Italics">S</span>-warfarin [<span class="Italics">see <a href="#i4i_pharmacokinetics_id_e65529dc-1dcb-4acd-8121-fafca9daaf03">Clinical Pharmacology</a> (<a href="#i4i_pharmacokinetics_id_e65529dc-1dcb-4acd-8121-fafca9daaf03">12.3</a>)</span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_drug_interaction_id_c7024004-c13e-4b8e-aa98-3ce0206182e6"></a><a name="section-7.5"></a><p></p>
<h2>7.5 Oral Contraceptives</h2>
<p class="First">In the presence of solifenacin there are no significant changes in the plasma concentrations of combined oral contraceptives (ethinyl estradiol/levonorgestrel) [<span class="Italics">see <a href="#i4i_pharmacokinetics_id_e65529dc-1dcb-4acd-8121-fafca9daaf03">Clinical Pharmacology</a> (<a href="#i4i_pharmacokinetics_id_e65529dc-1dcb-4acd-8121-fafca9daaf03">12.3</a>)</span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_drug_interaction_id_42a2e52f-dce3-42e1-9b92-a70501d9667a"></a><a name="section-7.6"></a><p></p>
<h2>7.6 Digoxin</h2>
<p class="First">Solifenacin had no significant effect on the pharmacokinetics of digoxin (0.125 mg/day) in healthy subjects [<span class="Italics">see <a href="#i4i_pharmacokinetics_id_e65529dc-1dcb-4acd-8121-fafca9daaf03">Clinical Pharmacology</a> (<a href="#i4i_pharmacokinetics_id_e65529dc-1dcb-4acd-8121-fafca9daaf03">12.3</a>)</span>].</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="i4i_specific_populations_id_de536d82-ce7d-4843-ad6d-8e034eac4c54"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="i4i_pregnancy_id_ab3c76c6-93c1-45ae-90d8-94d678b0e26d"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<p class="First"><span class="Bold">Pregnancy Category C</span></p>
<p>There are no adequate and well-controlled studies in pregnant women.</p>
<p>Reproduction studies have been performed in mice, rats and rabbits. After oral administration of <span class="Sup">14</span>C-solifenacin succinate to pregnant mice, drug-related material was shown to cross the placental barrier. No embryotoxicity or <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span> was observed in mice treated with 1.2 times (30 mg/kg/day) the expected exposure at the maximum recommended human dose [MRHD] of 10 mg. Administration of solifenacin succinate to pregnant mice at 3.6 times and greater (100 mg/kg/day and greater) the exposure at the MRHD, during the major period of organ development resulted in reduced fetal body weights. Administration of 7.9 times (250 mg/kg/day) the MRHD to pregnant mice resulted in an increased incidence of <span class="product-label-link" type="condition" conceptid="135923" conceptname="Cleft palate">cleft palate</span>. In utero and lactational exposures to maternal doses of solifenacin succinate of 3.6 times (100 mg/kg/day) the MRHD resulted in reduced peripartum and postnatal survival, reductions in body <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>, and delayed physical development (eye opening and vaginal patency). An increase in the percentage of male offspring was also observed in litters from offspring exposed to maternal doses of 250 mg/kg/day. No embryotoxic effects were observed in rats at up to 50 mg/kg/day (&lt;1 times the exposure at the MRHD) or in rabbits at up to 1.8 times (50 mg/kg/day) the exposure at the MRHD. Because animal reproduction studies are not always predictive of human response, VESIcare should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.</p>
</div>
<div class="Section" data-sectionCode="34079-4">
<a name="i4i_labour_delivery_id_62d70719-56f7-4769-b462-8768197140cd"></a><a name="section-8.2"></a><p></p>
<h2>8.2 Labor and Delivery</h2>
<p class="First">The effect of VESIcare on labor and delivery in humans has not been studied.</p>
<p>There were no effects on natural delivery in mice treated with 1.2 times (30 mg/kg/day) the expected exposure at the maximum recommended human dose [MRHD] of 10 mg. Administration of solifenacin succinate at 3.6 times (100 mg/kg/day) the exposure at the MRHD or greater increased peripartum pup mortality.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="i4i_nursing_mothers_id_eac811c6-2ad3-417d-8e41-5c77ecd086a0"></a><a name="section-8.3"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">After oral administration of <span class="Sup">14</span>C-solifenacin succinate to lactating mice, radioactivity was detected in maternal milk. There were no adverse observations in mice treated with 1.2 times (30 mg/kg/day) the expected exposure at the maximum recommended human dose [MRHD]. Pups of female mice treated with 3.6 times (100 mg/kg/day) the exposure at the MRHD or greater revealed reduced body weights, postpartum pup mortality or delays in the onset of reflex and physical development during the lactation period.</p>
<p>It is not known whether solifenacin is excreted in human milk. Because many drugs are excreted in human milk, VESIcare should not be administered during nursing. A decision should be made whether to discontinue nursing or to discontinue VESIcare in nursing mothers.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_id_4a4c58b7-b985-4bdf-8b98-3792ceb912f0"></a><a name="section-8.4"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">The safety and effectiveness of VESIcare in pediatric patients have not been established.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="i4i_geriatric_use_id_f84d922d-4d16-448c-882b-a3ed0888559d"></a><a name="section-8.5"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">In placebo-controlled clinical studies, similar safety and effectiveness were observed between older (623 patients ≥ 65 years and 189 patients ≥ 75 years) and younger patients (1188 patients &lt; 65 years) treated with VESIcare.</p>
<p>Multiple dose studies of VESIcare in elderly volunteers (65 to 80 years) showed that C<span class="Sub">max</span>, AUC and t<span class="Sub">1/2 </span>values were 20-25% higher as compared to the younger volunteers (18 to 55 years).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_19f5df28-2ad0-43d4-bd3b-4c4ae29fc17c"></a><a name="section-8.6"></a><p></p>
<h2>8.6 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First">VESIcare should be used with caution in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. There is a 2.1-fold increase in AUC and 1.6-fold increase in t<span class="Sub">1/2 </span>of solifenacin in patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. Doses of VESIcare greater than 5 mg are not recommended in patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (CL<span class="Sub">cr</span> &lt; 30 mL/min) [<span class="Italics">see <a href="#i4i_section_id_d44eeb38-983b-466a-87e6-1e4533058857">Warnings and Precautions</a> (<a href="#i4i_section_id_d44eeb38-983b-466a-87e6-1e4533058857">5.7</a>)</span>; <span class="Italics"><a href="#i4i_section_id_23bb397a-732b-4191-96c4-1dcf2c8299e7">Dosage and Administration</a> (<a href="#i4i_section_id_23bb397a-732b-4191-96c4-1dcf2c8299e7">2.2</a>)</span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_1aedf6cf-afc3-456f-91b0-61d49a9929a2"></a><a name="section-8.7"></a><p></p>
<h2>8.7 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<p class="First">VESIcare should be used with caution in patients with reduced hepatic function. There is a 2-fold increase in the t<span class="Sub">1/2 </span>and 35% increase in AUC of solifenacin in patients with moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. Doses of VESIcare greater than 5 mg are not recommended in patients with moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (Child-Pugh B). VESIcare is not recommended for patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (Child-Pugh C) [<span class="Italics">see <a href="#i4i_section_id_f5f8e5ea-2387-4f2d-8880-5bfddd0f2e24">Warnings and Precautions</a> (<a href="#i4i_section_id_f5f8e5ea-2387-4f2d-8880-5bfddd0f2e24">5.6</a>); <a href="#i4i_section_id_23bb397a-732b-4191-96c4-1dcf2c8299e7">Dosage and Administration</a> (<a href="#i4i_dosage_admin_duplicate_id_728ae196-b8f7-4d34-a921-87f546f1d41c">2.3</a>)</span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_8291ba12-9206-453d-ba27-150839302e8d"></a><a name="section-8.8"></a><p></p>
<h2>8.8 Gender</h2>
<p class="First">The pharmacokinetics of solifenacin is not significantly influenced by gender.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="i4i_overdosage_id_2d3621cf-3490-443a-abfb-4d09a747b624"></a><a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<p class="First">Overdosage with VESIcare can potentially result in severe anticholinergic effects and should be treated accordingly. The highest dose ingested in an accidental <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> of solifenacin succinate was 280 mg in a 5-hour period. This case was associated with <span class="product-label-link" type="condition" conceptid="436222" conceptname="Altered mental status">mental status changes</span>. Some cases reported a decrease in the level of consciousness. </p>
<p>Intolerable anticholinergic side effects (fixed and <span class="product-label-link" type="condition" conceptid="4290615" conceptname="Dilated pupil">dilated pupils</span>, <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>, failure of heel-to-toe exam, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremors</span> and <span class="product-label-link" type="condition" conceptid="4039266" conceptname="Dry skin">dry skin</span>) occurred on day 3 in normal volunteers taking 50 mg daily (5 times the maximum recommended therapeutic dose) and resolved within 7 days following discontinuation of drug.</p>
<p>In the event of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> with VESIcare, treat with gastric lavage and appropriate supportive measures. ECG monitoring is also recommended.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_3a7e60be-f3fb-47b5-b216-7229c6e8fe0e"></a><a name="section-10"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">VESIcare<span class="Sup">®</span> (solifenacin succinate) is a muscarinic receptor antagonist. Chemically, solifenacin succinate is butanedioic acid, compounded with (1<span class="Italics">S</span>)-(3<span class="Italics">R</span>)-1-azabicyclo[2.2.2]oct-3-yl 3,4-dihydro-1-phenyl-2(1<span class="Italics">H</span>)-iso-quinolinecarboxylate (1:1) having an empirical formula of C<span class="Sub">23</span>H<span class="Sub">26</span>N<span class="Sub">2</span>O<span class="Sub">2</span>•C<span class="Sub">4</span>H<span class="Sub">6</span>O<span class="Sub">4</span>, and a molecular weight of 480.55. The structural formula of solifenacin succinate is:</p>
<div class="Figure">
<a name="id1067"></a><img alt="structure of Solifenacin succinate " src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=5256f116-ad56-4ce0-8a5e-69d401f3ea00&amp;name=9d4c0f37-4aa2-4b61-a643-444519206779-01.jpg">
</div>
<p>Solifenacin succinate is a white to <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span>-yellowish-white crystal or crystalline powder. It is freely soluble at room temperature in water, glacial acetic acid, dimethyl sulfoxide, and methanol. Each VESIcare tablet contains 5 or 10 mg of solifenacin succinate and is formulated for oral administration. In addition to the active ingredient solifenacin succinate, each VESIcare tablet also contains the following inert ingredients: lactose monohydrate, corn starch, hypromellose 2910, magnesium stearate, talc, polyethylene glycol 8000 and titanium dioxide with yellow ferric oxide (5 mg VESIcare tablet) or red ferric oxide (10 mg VESIcare tablet).</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_fc39e285-cfac-4aaa-b5b5-2384b93ffa64"></a><a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="i4i_mechanism_action_id_ca87e0b8-e83e-40e5-9fb7-206149d53dd7"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">Solifenacin is a competitive muscarinic receptor antagonist. Muscarinic receptors play an important role in several major cholinergically mediated functions, including contractions of urinary bladder smooth muscle and stimulation of salivary secretion.</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="i4i_pharmacodynamics_id_a3f06821-84cd-476d-b6e7-69d954d7f054"></a><a name="section-11.2"></a><p></p>
<h2>12.2 Pharmacodynamics</h2>
<p class="First"><span class="Bold"><span class="Italics">Cardiac Electrophysiology</span></span></p>
<p>The effect of 10 mg and 30 mg solifenacin succinate on the QT interval was evaluated at the time of peak plasma concentration of solifenacin in a multi-dose, randomized, double-blind, placebo and positive-controlled (moxifloxacin 400 mg) trial. Subjects were randomized to one of two treatment groups after receiving placebo and moxifloxacin sequentially. One group (n=51) went on to complete 3 additional sequential periods of dosing with solifenacin 10, 20, and 30 mg while the second group (n=25) in parallel completed a sequence of placebo and moxifloxacin. Study subjects were female volunteers aged 19 to 79 years. The 30 mg dose of solifenacin succinate (three times the highest recommended dose) was chosen for use in this study because this dose results in a solifenacin exposure that covers those observed upon co-administration of 10 mg VESIcare with potent CYP3A4 inhibitors (e.g. ketoconazole, 400 mg). Due to the sequential dose escalating nature of the study, baseline EKG measurements were separated from the final QT assessment (of the 30 mg dose level) by 33 days.</p>
<p>The median difference from baseline in heart rate associated with the 10 and 30 mg doses of solifenacin succinate compared to placebo was -2 and 0 beats/minute, respectively. Because a significant period effect on QTc was observed, the QTc effects were analyzed utilizing the parallel placebo control arm rather than the pre-specified intra-patient analysis. Representative results are shown in <a href="#_Ref369255844">Table 2</a>.</p>
<a name="_Ref369255844"></a><table width="100%">
<caption><span>Table 2. QTc changes in msec (90%CI) from baseline at Tmax (relative to placebo)<a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a></span></caption>
<col width="35%">
<col width="65%">
<thead><tr class="First Last">
<th class="Botrule Lrule Rrule Toprule" align="left" valign="top"><span class="Bold">Drug/Dose</span></th>
<th class="Botrule Rrule Toprule" align="left" valign="top">
<span class="Bold">Fridericia method </span><br><span class="Bold">(using mean difference)</span>
</th>
</tr></thead>
<tfoot><tr><td colspan="2" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>Results displayed are those derived from the parallel design portion of the study and represent the comparison of Group 1 to time-matched placebo effects in Group 2</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">Solifenacin 10 mg</p></td>
<td class="Botrule Rrule Toprule" align="center" valign="top"><p class="First">2 (-3,6)</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Solifenacin 30 mg </p></td>
<td class="Botrule Rrule" align="center" valign="top"><p class="First">8 (4,13)</p></td>
</tr>
</tbody>
</table>
<p>Moxifloxacin was included as a positive control in this study and, given the length of the study, its effect on the QT interval was evaluated in 3 different sessions. The placebo subtracted mean changes (90% CI) in QTcF for moxifloxacin in the three sessions were 11 (7, 14), 12 (8, 17), and 16 (12, 21), respectively.</p>
<p>The QT interval prolonging effect appeared greater for the 30 mg compared to the 10 mg dose of solifenacin. Although the effect of the highest solifenacin dose (three times the maximum therapeutic dose) studied did not appear as large as that of the positive control moxifloxacin at its therapeutic dose, the confidence intervals overlapped. This study was not designed to draw direct statistical conclusions between the drugs or the dose levels.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="i4i_pharmacokinetics_id_e65529dc-1dcb-4acd-8121-fafca9daaf03"></a><a name="section-11.3"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First"><span class="Bold"><span class="Italics">Absorption</span></span></p>
<p>After oral administration of VESIcare to healthy volunteers, peak plasma levels (C<span class="Sub">max</span>) of solifenacin are reached within 3 to 8 hours after administration, and at steady state ranged from 32.3 to 62.9 ng/mL for the 5 and 10 mg VESIcare tablets, respectively. The absolute bioavailability of solifenacin is approximately 90%, and plasma concentrations of solifenacin are proportional to the dose administered.<br><br><br><span class="Bold"><span class="Italics">Effect of food</span></span></p>
<p>VESIcare may be administered without regard to meals. A single 10 mg dose administration of VESIcare with food increased C<span class="Sub">max</span> and AUC by 4% and 3%, respectively.<br><br><br><span class="Bold"><span class="Italics">Distribution</span></span></p>
<p>Solifenacin is approximately 98% (<span class="Italics">in vivo</span>) bound to human plasma proteins, principally to ?<span class="Sub">1</span>-acid glycoprotein. Solifenacin is highly distributed to non-CNS tissues, having a mean steady-state volume of distribution of 600L.<br><br><br><span class="Bold"><span class="Italics">Metabolism</span></span></p>
<p>Solifenacin is extensively metabolized in the liver. The primary pathway for elimination is by way of CYP3A4; however, alternate metabolic pathways exist. The primary metabolic routes of solifenacin are through N-oxidation of the quinuclidin ring and 4R-hydroxylation of tetrahydroisoquinoline ring. One pharmacologically active metabolite (4R-hydroxy solifenacin), occurring at low concentrations and unlikely to contribute significantly to clinical activity, and three pharmacologically inactive metabolites (N-glucuronide and the N-oxide and 4R-hydroxy-N-oxide of solifenacin) have been found in human plasma after oral dosing.<br><br><br><span class="Bold"><span class="Italics">Excretion</span></span></p>
<p>Following the administration of 10 mg of <span class="Sup">14</span>C-solifenacin succinate to healthy volunteers, 69.2% of the radioactivity was recovered in the urine and 22.5% in the feces over 26 days. Less than 15% (as mean value) of the dose was recovered in the urine as intact solifenacin. The major metabolites identified in urine were N-oxide of solifenacin, 4R-hydroxy solifenacin and 4R-hydroxy-N-oxide of solifenacin and in feces 4R-hydroxy solifenacin. The elimination half-life of solifenacin following chronic dosing is approximately 45-68 hours.<br><br><br><span class="Bold"><span class="Italics">Drug Interactions</span></span><br><br><br><span class="Underline">Potent CYP3A4 Inhibitors</span></p>
<p>In a crossover study, following blockade of CYP3A4 by coadministration of the potent CYP3A4 inhibitor, ketoconazole 400 mg, once daily for 21 days, the mean C<span class="Sub">max</span> and AUC of solifenacin increased by 1.5 and 2.7-fold, respectively [<span class="Italics">see <a href="#i4i_section_id_9fb6f61b-bddf-4919-95d2-eb71856fa4f9">Dosage and Administration</a> (<a href="#i4i_section_id_9fb6f61b-bddf-4919-95d2-eb71856fa4f9">2.4</a>) and <a href="#i4i_section_id_f85b52ec-6611-4cd9-9b51-729288ed8e1b">Drug Interactions</a> (<a href="#i4i_section_id_f85b52ec-6611-4cd9-9b51-729288ed8e1b">7.1</a>)</span>]<span class="Bold">.</span><br><br><br><span class="Underline">Warfarin </span></p>
<p>In a crossover study, subjects received a single oral dose of warfarin 25 mg on the 10<span class="Sup">th</span> day of dosing with either solifenacin 10 mg or matching placebo once daily for 16 days. For <span class="Italics">R</span>-warfarin when it was coadministered with solifenacin, the mean C<span class="Sub">max</span> increased by 3% and AUC decreased by 2%. For <span class="Italics">S</span>-warfarin when it was coadministered with solifenacin, the mean C<span class="Sub">max</span> and AUC increased by 5% and 1%, respectively [<span class="Italics">see <a href="#i4i_section_id_4299cfa7-ecb5-4e51-b8e0-f4bae31d2829">Drug Interactions</a> (<a href="#i4i_section_id_4299cfa7-ecb5-4e51-b8e0-f4bae31d2829">7.4</a>)</span>].<br><br><br><span class="Underline">Oral Contraceptives </span></p>
<p>In a crossover study, subjects received 2 cycles of 21 days of oral contraceptives containing 30 ug ethinyl estradiol and 150 ug levonorgestrel. During the second cycle, subjects received additional solifenacin 10 mg or matching placebo once daily for 10 days starting from 12<span class="Sup">th</span> day of receipt of oral contraceptives. For ethinyl estradiol when it was administered with solifenacin, the mean C<span class="Sub">max</span> and AUC increased by 2% and 3%, respectively. For levonorgestrel when it was administered with solifenacin, the mean C<span class="Sub">max</span> and AUC decreased by 1% [<span class="Italics">see <a href="#i4i_drug_interaction_id_c7024004-c13e-4b8e-aa98-3ce0206182e6">Drug Interactions</a> (<a href="#i4i_drug_interaction_id_c7024004-c13e-4b8e-aa98-3ce0206182e6">7.5</a>)</span>].<br><br><br><span class="Underline">Digoxin </span></p>
<p>In a crossover study, subjects received digoxin (loading dose of 0.25 mg on day 1, followed by 0.125 mg from days 2 to 8) for 8 days. Consecutively, they received solifenacin 10 mg or matching placebo with digoxin 0.125 mg for additional 10 days. When digoxin was coadministered with solifenacin, the mean C<span class="Sub">max</span> and AUC increased by 13% and 4%, respectively [<span class="Italics">see <a href="#i4i_drug_interaction_id_42a2e52f-dce3-42e1-9b92-a70501d9667a">Drug Interactions</a> (<a href="#i4i_drug_interaction_id_42a2e52f-dce3-42e1-9b92-a70501d9667a">7.6</a>)</span>].</p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="i4i_nonclinical_toxicology_id_14d23e70-a546-4bb7-86dc-97f6b5add4ab"></a><a name="section-12"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="i4i_carcinogenesis_mutagenesis_fertility_id_851aeee2-faae-4175-ba24-d028b2f7f656"></a><a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">No increase in tumors was found following the administration of solifenacin succinate to male and female mice for 104 weeks at doses up to 200 mg/kg/day (5 and 9 times, respectively, of the exposure at the maximum recommended human dose [MRHD] of 10 mg), and male and female rats for 104 weeks at doses up to 20 and 15 mg/kg/day, respectively (&lt;1 times the exposure at the MRHD).</p>
<p>Solifenacin succinate was not mutagenic in the <span class="Italics">in vitro <span class="product-label-link" type="condition" conceptid="4235289" conceptname="Salmonellosis">Salmonella</span> typhimurium </span>or <span class="Italics">Escherichia coli </span>microbial mutagenicity test or chromosomal aberration test in human peripheral blood <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span> with or without metabolic activation, or in the <span class="Italics">in vivo</span> micronucleus test in rats.</p>
<p>Solifenacin succinate had no effect on reproductive function, fertility or early embryonic development of the fetus in male and female mice treated with 250 mg/kg/day (13 times the exposure at the MRHD) of solifenacin succinate, and in male rats treated with 50 mg/kg/day (&lt;1 times the exposure at the MRHD) and female rats treated with 100 mg/kg/day (1.7 times the exposure at the MRHD) of solifenacin succinate.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="i4i_clinical_studies_id_a85b6a73-22fa-4d75-94bd-731e9611902f"></a><a name="section-13"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<p class="First">VESIcare was evaluated in four twelve-week, double-blind, randomized, placebo-controlled, parallel group, multicenter clinical trials for the treatment of <span class="product-label-link" type="condition" conceptid="76153" conceptname="Low compliance bladder">overactive bladder</span> in patients having symptoms of <span class="product-label-link" type="condition" conceptid="4012368" conceptname="Increased frequency of urination">urinary frequency</span>, urgency, and/or urge or mixed <span class="product-label-link" type="condition" conceptid="444035" conceptname="Incontinence">incontinence</span> (with a predominance of urge). Entry criteria required that patients have symptoms of <span class="product-label-link" type="condition" conceptid="76153" conceptname="Low compliance bladder">overactive bladder</span> for ≥ 3 months duration. These studies involved 3027 patients (1811 on VESIcare and 1216 on placebo), and approximately 90% of these patients completed the 12-week studies. Two of the four studies evaluated the 5 and 10 mg VESIcare doses and the other two evaluated only the 10 mg dose. All patients completing the 12-week studies were eligible to enter an open label, long term extension study and 81% of patients enrolling completed the additional 40-week treatment period. The majority of patients were Caucasian (93%) and female (80%) with a mean age of 58 years.</p>
<p>The primary endpoint in all four trials was the mean change from baseline to 12 weeks in number of micturitions/24 hours. Secondary endpoints included mean change from baseline to 12 weeks in number of <span class="product-label-link" type="condition" conceptid="444035" conceptname="Incontinence">incontinence</span> episodes/24 hours, and mean volume voided per micturition. The efficacy of VESIcare was similar across patient age and gender. The mean reduction in the number of micturitions per 24 hours was significantly greater with VESIcare 5 mg (2.3; p&lt;0.001) and VESIcare 10 mg (2.7; p&lt;0.001) compared to placebo, (1.4).</p>
<p>The mean reduction in the number of <span class="product-label-link" type="condition" conceptid="444035" conceptname="Incontinence">incontinence</span> episodes per 24 hours was significantly greater with VESIcare 5 mg (1.5; p&lt;0.001) and VESIcare 10 mg (1.8; p&lt;0.001) treatment groups compared to placebo (1.1). The mean increase in the volume voided per micturition was significantly greater with VESIcare 5 mg (32.3 mL; p&lt;0.001) and VESIcare 10 mg (42.5 mL; p&lt;0.001) compared with placebo (8.5 mL).</p>
<p>The results for the primary and secondary endpoints in the four individual 12-week clinical studies of VESIcare are reported in <a href="#_Ref369255871">Table 3</a> through <a href="#_Ref369255891">6</a>.</p>
<a name="_Ref369255871"></a><table width="100%">
<caption><span>Table 3. Mean Change from Baseline to Endpoint for VESIcare (5 mg and 10 mg daily) and Placebo: Study 1</span></caption>
<col width="47%">
<col width="18%">
<col width="18%">
<col width="17%">
<thead><tr class="First Last">
<th class="Botrule Lrule Rrule Toprule" align="left" valign="top"><span class="Bold">Parameter</span></th>
<th class="Botrule Rrule Toprule" align="left" valign="top">
<span class="Bold">Placebo</span><br><span class="Bold">(N=253)</span><br><span class="Bold">Mean (SE)</span>
</th>
<th class="Botrule Rrule Toprule" align="left" valign="top">
<span class="Bold">VESIcare</span><br><span class="Bold">5 mg</span><br><span class="Bold">(N=266)</span><br><span class="Bold">Mean (SE)</span>
</th>
<th class="Botrule Rrule Toprule" align="left" valign="top">
<span class="Bold">VESIcare</span><br><span class="Bold">10 mg</span><br><span class="Bold">(N=264)</span><br><span class="Bold">Mean (SE)</span>
</th>
</tr></thead>
<tfoot><tr><td colspan="4" align="left"><dl class="Footnote">
<dt><a name="footnote-2" href="#footnote-reference-2">*</a></dt>
<dd>Primary endpoint</dd>
<dt><a name="footnote-3" href="#footnote-reference-3">†</a></dt>
<dd>Secondary endpoint</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4012368" conceptname="Increased frequency of urination">Urinary Frequency</span> (Number of Micturitions/24 hours)<a name="footnote-reference-2" href="#footnote-2" class="Sup">*</a></p></td>
<td class="Botrule Rrule Toprule" valign="top"></td>
<td class="Botrule Rrule Toprule" valign="top"></td>
<td class="Botrule Rrule Toprule" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top">
<p class="First"> Baseline</p>
<p> Reduction</p>
<p> P value vs. placebo</p>
</td>
<td class="Botrule Rrule" valign="top">
<p class="First">12.2 (0.26)</p>
<p>1.2 (0.21)</p>
</td>
<td class="Botrule Rrule" valign="top">
<p class="First">12.1 (0.24)</p>
<p>2.2 (0.18)</p>
<p> &lt;0.001</p>
</td>
<td class="Botrule Rrule" valign="top">
<p class="First">12.3 (0.24)</p>
<p>2.6 (0.20)</p>
<p> &lt;0. 001</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Number of <span class="product-label-link" type="condition" conceptid="444035" conceptname="Incontinence">Incontinence</span> Episodes/24 hours<a name="footnote-reference-3" href="#footnote-3" class="Sup">†</a></p></td>
<td class="Botrule Rrule" valign="top"></td>
<td class="Botrule Rrule" valign="top"></td>
<td class="Botrule Rrule" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top">
<p class="First"> Baseline</p>
<p> Reduction</p>
<p> P value vs. placebo</p>
</td>
<td class="Botrule Rrule" valign="top">
<p class="First">2.7 (0.23)</p>
<p>0.8 (0.18)</p>
</td>
<td class="Botrule Rrule" valign="top">
<p class="First">2.6 (0.22)</p>
<p>1.4 (0.15)</p>
<p> &lt;0.01</p>
</td>
<td class="Botrule Rrule" valign="top">
<p class="First">2.6 (0.23)</p>
<p>1.5 (0.18)</p>
<p> &lt;0.01</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Volume Voided per micturition [mL]<a href="#footnote-3" class="Sup">†</a></p></td>
<td class="Botrule Rrule" valign="top"></td>
<td class="Botrule Rrule" valign="top"></td>
<td class="Botrule Rrule" valign="top"></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" valign="top">
<p class="First"> Baseline</p>
<p> Increase</p>
<p> P value vs. placebo</p>
</td>
<td class="Botrule Rrule" valign="top">
<p class="First">143.8 (3.37)</p>
<p>7.4 (2.28)</p>
</td>
<td class="Botrule Rrule" valign="top">
<p class="First">149.6 (3.35)</p>
<p>32.9 (2.92)</p>
<p> &lt;0.001</p>
</td>
<td class="Botrule Rrule" valign="top">
<p class="First">147.2 (3.15)</p>
<p>39.2 (3.11)</p>
<p> &lt;0.001</p>
</td>
</tr>
</tbody>
</table>
<a name="_RefID0EI2AG"></a><table width="100%">
<caption><span>Table 4. Mean Change from Baseline to Endpoint for VESIcare (5 mg and 10 mg daily) and Placebo: Study 2</span></caption>
<col width="47%">
<col width="18%">
<col width="18%">
<col width="17%">
<thead><tr class="First Last">
<th class="Botrule Lrule Rrule Toprule" align="left" valign="top"><span class="Bold">Parameter</span></th>
<th class="Botrule Rrule Toprule" align="left" valign="top">
<span class="Bold">Placebo</span><br><span class="Bold">(N=281)</span><br><span class="Bold">Mean (SE)</span>
</th>
<th class="Botrule Rrule Toprule" align="left" valign="top">
<span class="Bold">VESIcare</span><br><span class="Bold">5 mg</span><br><span class="Bold">(N=286)</span><br><span class="Bold">Mean (SE)</span>
</th>
<th class="Botrule Rrule Toprule" align="left" valign="top">
<span class="Bold">VESIcare</span><br><span class="Bold">10 mg</span><br><span class="Bold">(N=290)</span><br><span class="Bold">Mean (SE)</span>
</th>
</tr></thead>
<tfoot><tr><td colspan="4" align="left"><dl class="Footnote">
<dt><a name="footnote-4" href="#footnote-reference-4">*</a></dt>
<dd>Primary endpoint</dd>
<dt><a name="footnote-5" href="#footnote-reference-5">†</a></dt>
<dd>Secondary endpoint</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4012368" conceptname="Increased frequency of urination">Urinary Frequency</span> (Number of Micturitions/24 hours)<a name="footnote-reference-4" href="#footnote-4" class="Sup">*</a></p></td>
<td class="Botrule Rrule Toprule" valign="top"></td>
<td class="Botrule Rrule Toprule" valign="top"></td>
<td class="Botrule Rrule Toprule" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top">
<p class="First"> Baseline</p>
<p> Reduction</p>
<p> P value vs. placebo</p>
</td>
<td class="Botrule Rrule" valign="top">
<p class="First">12.3 (0.23)</p>
<p>1.7 (0.19)</p>
</td>
<td class="Botrule Rrule" valign="top">
<p class="First">12.1 (0.23)</p>
<p>2.4 (0.17)</p>
<p>&lt;0.001</p>
</td>
<td class="Botrule Rrule" valign="top">
<p class="First">12.1 (0.21)</p>
<p>2.9 (0.18)</p>
<p>&lt;0. 001</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Number of <span class="product-label-link" type="condition" conceptid="444035" conceptname="Incontinence">Incontinence</span> Episodes/24 hours<a name="footnote-reference-5" href="#footnote-5" class="Sup">†</a></p></td>
<td class="Botrule Rrule" valign="top"></td>
<td class="Botrule Rrule" valign="top"></td>
<td class="Botrule Rrule" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top">
<p class="First"> Baseline</p>
<p> Reduction</p>
<p> P value vs. placebo</p>
</td>
<td class="Botrule Rrule" valign="top">
<p class="First">3.2 (0.24)</p>
<p>1.3 (0.19)</p>
</td>
<td class="Botrule Rrule" valign="top">
<p class="First">2.6 (0.18)</p>
<p>1.6 (0.16)</p>
<p>&lt;0.01</p>
</td>
<td class="Botrule Rrule" valign="top">
<p class="First">2.8 (0.20)</p>
<p>1.6 (0.18)</p>
<p>0.016</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Volume Voided per micturition [mL]<a href="#footnote-5" class="Sup">†</a></p></td>
<td class="Botrule Rrule" valign="top"></td>
<td class="Botrule Rrule" valign="top"></td>
<td class="Botrule Rrule" valign="top"></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" valign="top">
<p class="First"> Baseline</p>
<p> Increase</p>
<p> P value vs. placebo</p>
</td>
<td class="Botrule Rrule" valign="top">
<p class="First">147.2 (3.18)</p>
<p>11.3 (2.52)</p>
</td>
<td class="Botrule Rrule" valign="top">
<p class="First">148.5 (3.16)</p>
<p>31.8 (2.94)</p>
<p>&lt;0.001</p>
</td>
<td class="Botrule Rrule" valign="top">
<p class="First">145.9 (3.42)</p>
<p>36.6 (3.04)</p>
<p>&lt;0.001</p>
</td>
</tr>
</tbody>
</table>
<a name="_RefID0EYABG"></a><table width="100%">
<caption><span>Table 5. Mean Change from Baseline to Endpoint for VESIcare (10 mg daily) and Placebo: Study 3</span></caption>
<col width="56%">
<col width="22%">
<col width="22%">
<thead><tr class="First Last">
<th class="Botrule Lrule Rrule Toprule" align="left" valign="top"><span class="Bold">Parameter</span></th>
<th class="Botrule Rrule Toprule" align="left" valign="top">
<span class="Bold">Placebo</span><br><span class="Bold">(N=309)</span><br><span class="Bold">Mean (SE)</span>
</th>
<th class="Botrule Rrule Toprule" align="left" valign="top">
<span class="Bold">VESIcare</span><br><span class="Bold">10 mg</span><br><span class="Bold">(N=306)</span><br><span class="Bold">Mean (SE)</span>
</th>
</tr></thead>
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-6" href="#footnote-reference-6">*</a></dt>
<dd>Primary endpoint</dd>
<dt><a name="footnote-7" href="#footnote-reference-7">†</a></dt>
<dd>Secondary endpoint</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4012368" conceptname="Increased frequency of urination">Urinary Frequency</span> (Number of Micturitions/24 hours)<a name="footnote-reference-6" href="#footnote-6" class="Sup">*</a></p></td>
<td class="Botrule Rrule Toprule" valign="top"></td>
<td class="Botrule Rrule Toprule" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top">
<p class="First"> Baseline</p>
<p> Reduction</p>
<p> P value vs. placebo</p>
</td>
<td class="Botrule Rrule" valign="top">
<p class="First">11.5 (0.18)</p>
<p>1.5 (0.15)</p>
</td>
<td class="Botrule Rrule" valign="top">
<p class="First">11.7 (0.18)</p>
<p>3.0 (0.15)</p>
<p>&lt;0. 001</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Number of <span class="product-label-link" type="condition" conceptid="444035" conceptname="Incontinence">Incontinence</span> Episodes/24 hours<a name="footnote-reference-7" href="#footnote-7" class="Sup">†</a></p></td>
<td class="Botrule Rrule" valign="top"></td>
<td class="Botrule Rrule" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top">
<p class="First"> Baseline</p>
<p> Reduction</p>
<p> P value vs. placebo</p>
</td>
<td class="Botrule Rrule" valign="top">
<p class="First">3.0 (0.20)</p>
<p>1.1 (0.16)</p>
</td>
<td class="Botrule Rrule" valign="top">
<p class="First">3.1 (0.22)</p>
<p>2.0 (0.19)</p>
<p>&lt;0.001</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Volume Voided per micturition [mL]<a href="#footnote-7" class="Sup">†</a></p></td>
<td class="Botrule Rrule" valign="top"></td>
<td class="Botrule Rrule" valign="top"></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" valign="top">
<p class="First"> Baseline</p>
<p> Increase</p>
<p> P value vs. placebo</p>
</td>
<td class="Botrule Rrule" valign="top">
<p class="First">190.3 (5.48)</p>
<p>2.7 (3.15)</p>
</td>
<td class="Botrule Rrule" valign="top">
<p class="First">183.5 (4.97)</p>
<p>47.2 (3.79)</p>
<p>&lt;0.001</p>
</td>
</tr>
</tbody>
</table>
<a name="_Ref369255891"></a><table width="100%">
<caption><span>Table 6. Mean Change from Baseline to Endpoint for VESIcare (10 mg daily) and Placebo: Study 4</span></caption>
<col width="56%">
<col width="22%">
<col width="22%">
<thead><tr class="First Last">
<th class="Botrule Lrule Rrule Toprule" align="left" valign="top"><span class="Bold">Parameter</span></th>
<th class="Botrule Rrule Toprule" align="left" valign="top">
<span class="Bold">Placebo</span><br><span class="Bold">(N=295)</span><br><span class="Bold">Mean (SE)</span>
</th>
<th class="Botrule Rrule Toprule" align="left" valign="top">
<span class="Bold">VESIcare</span><br><span class="Bold">10 mg</span><br><span class="Bold">(N=298)</span><br><span class="Bold">Mean (SE)</span>
</th>
</tr></thead>
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-8" href="#footnote-reference-8">*</a></dt>
<dd>Primary endpoint</dd>
<dt><a name="footnote-9" href="#footnote-reference-9">†</a></dt>
<dd>Secondary endpoint</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4012368" conceptname="Increased frequency of urination">Urinary Frequency</span> (Number of Micturitions/24 hours)<a name="footnote-reference-8" href="#footnote-8" class="Sup">*</a></p></td>
<td class="Botrule Rrule Toprule" valign="top"></td>
<td class="Botrule Rrule Toprule" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top">
<p class="First"> Baseline</p>
<p> Reduction</p>
<p> P value vs. placebo</p>
</td>
<td class="Botrule Rrule" valign="top">
<p class="First">11.8 (0.18)</p>
<p>1.3 (0.16)</p>
</td>
<td class="Botrule Rrule" valign="top">
<p class="First">11.5 (0.18)</p>
<p>2.4 (0.15)</p>
<p>&lt;0. 001</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Number of <span class="product-label-link" type="condition" conceptid="444035" conceptname="Incontinence">Incontinence</span> Episodes/24 hours<a name="footnote-reference-9" href="#footnote-9" class="Sup">†</a></p></td>
<td class="Botrule Rrule" valign="top"></td>
<td class="Botrule Rrule" valign="top"></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top">
<p class="First"> Baseline</p>
<p> Reduction</p>
<p> P value vs. placebo</p>
</td>
<td class="Botrule Rrule" valign="top">
<p class="First">2.9 (0.18)</p>
<p>1.2 (0.15)</p>
</td>
<td class="Botrule Rrule" valign="top">
<p class="First">2.9 (0.17)</p>
<p>2.0 (0.15)</p>
<p>&lt;0.001</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Volume Voided per micturition [mL]<a href="#footnote-9" class="Sup">†</a></p></td>
<td class="Botrule Rrule" valign="top"></td>
<td class="Botrule Rrule" valign="top"></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" valign="top">
<p class="First"> Baseline</p>
<p> Increase</p>
<p> P value vs. placebo</p>
</td>
<td class="Botrule Rrule" valign="top">
<p class="First">175.7 (4.44)</p>
<p>13.0 (3.45)</p>
</td>
<td class="Botrule Rrule" valign="top">
<p class="First">174.1 (4.15)</p>
<p>46.4 (3.73)</p>
<p>&lt;0.001</p>
</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_ec55153e-390c-4251-965e-c5be2771ff11"></a><a name="section-14"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">VESIcare is supplied as round, film-coated tablets, available in bottles and unit dose <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> packages as follows: </p>
<p>Each 5 mg tablet is light yellow and debossed with a logo and “150? and is available in bottles of 4590 tablets, NDC 55154-3877-8 and in bottles of 3240 tablets, NDC 55154-3877-2</p>
<p>Each 10 mg tablet is light pink and debossed with a logo and “151? and is available in bottles of 4590 tablets, NDC 55154-3878-8 and in bottles of 3240 tablets, NDC 55154-3878-2.</p>
<p>Repackaged By:</p>
<p>Cardinal Health</p>
<p>Zanesville, OH 43701</p>
<p>Store at 25ºC (77ºF) with excursions permitted from 15ºC to 30ºC (59°F-86ºF) [see USP Controlled Room Temperature].</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="i4i_info_patients_id_f59dcd99-1a01-4619-bec3-5a883a94f512"></a><a name="section-15"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<p class="First">See <a href="#ID_5b4ae88b-dbe9-4ffd-afde-718dd255cb5f">FDA-approved patient labeling (Patient Information)</a>.</p>
<p>Patients should be informed that antimuscarinic agents such as VESIcare have been associated with <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span> and <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>. Patients should be advised to contact their physician if they experience severe <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span> or become constipated for 3 or more days. Because VESIcare may cause <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>, patients should be advised to exercise caution in decisions to engage in potentially dangerous activities until the drug’s effect on the patient’s vision has been determined. <span class="product-label-link" type="condition" conceptid="437744" conceptname="Heat exhaustion">Heat prostration</span> (due to decreased <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>) can occur when anticholinergic drugs, such as VESIcare, are used in a hot environment. Patients should read the patient leaflet entitled “Patient Information VESIcare? before starting therapy with VESIcare.</p>
<p>Patients should be informed that solifenacin may produce <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, which could result in life-threatening airway obstruction. Patients should be advised to promptly discontinue solifenacin therapy and seek immediate attention if they experience <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> of the tongue or laryngopharynx, or <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">difficulty breathing</span>.<br></p>
</div>
<div class="Section" data-sectionCode="42230-3">
<a name="ID_5b4ae88b-dbe9-4ffd-afde-718dd255cb5f"></a><a name="section-16"></a><p></p>
<h1>FDA Approved Patient Labeling</h1>
<p class="First"><span class="Bold">VESIcare<span class="Sup">®</span> (VES-ih-care) </span></p>
<p><span class="Bold">(solifenacin succinate) </span></p>
<p><span class="Bold">Tablet</span><br><br><br>Read the Patient Information that comes with VESIcare before you start taking it and each time you get a refill. There may be new information. This leaflet does not take the place of talking with your doctor about your medical condition or treatment.<br><br><br><span class="Bold">What is VESIcare?</span></p>
<p>VESIcare is a prescription medicine for <span class="Bold">adults</span> used to treat the following symptoms due to a condition called <span class="Bold"><span class="product-label-link" type="condition" conceptid="76153" conceptname="Low compliance bladder">overactive bladder</span></span>:</p>
<dl>
<dt>•</dt>
<dd>Urge <span class="product-label-link" type="condition" conceptid="197672" conceptname="Urinary incontinence">urinary incontinence</span>: a strong need to urinate with leaking or wetting <span class="product-label-link" type="condition" conceptid="440279" conceptname="Accident">accidents</span></dd>
<dt>•</dt>
<dd>Urgency: a strong need to urinate right away</dd>
<dt>•</dt>
<dd>Frequency: urinating often</dd>
</dl>
<p>It is not known if VESIcare is safe and effective in children.<br><br><br><span class="Bold">Who should NOT take VESIcare?</span></p>
<p>Do not take VESIcare if you:</p>
<dl>
<dt>•</dt>
<dd>are not able to empty your bladder (<span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">urinary retention</span>)</dd>
<dt>•</dt>
<dd>have delayed or slow emptying of your stomach (gastric retention)</dd>
<dt>•</dt>
<dd>have an eye problem called “uncontrolled narrow-angle glaucoma?</dd>
<dt>•</dt>
<dd>are allergic to solifenacin succinate or any of the ingredients in VESIcare. See the end of this leaflet for a complete list of ingredients.<br><br>
</dd>
</dl>
<p><span class="Bold">What should I tell my doctor before taking VESIcare?</span></p>
<p>Before you take VESIcare, tell your doctor if you:</p>
<dl>
<dt>•</dt>
<dd>have any stomach or intestinal problems or problems with <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span></dd>
<dt>•</dt>
<dd>have trouble emptying your bladder or you have a weak urine stream</dd>
<dt>•</dt>
<dd>have an eye problem called "narrow angle <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>"</dd>
<dt>•</dt>
<dd>have liver problems</dd>
<dt>•</dt>
<dd>have kidney problems</dd>
<dt>•</dt>
<dd>have a rare heart problem called "QT prolongation"</dd>
<dt>•</dt>
<dd>are pregnant or plan to become pregnant. It is not known if VESIcare will harm your unborn baby. Talk to your doctor if you are pregnant or plan to become pregnant.</dd>
<dt>•</dt>
<dd>are breastfeeding or plan to breastfeed. It is not known if VESIcare passes into your breast milk. You and your doctor should decide if you will take VESIcare or breastfeed. You should not do both.</dd>
</dl>
<p><span class="Bold">Tell your doctor about all the medicines you take</span>, including prescription and nonprescription medicines, vitamins, and herbal supplements. VESIcare may affect the way other medicines work, and other medicines may affect how VESIcare works.<br><br><br><span class="Bold">How should I take VESIcare?</span></p>
<dl>
<dt>•</dt>
<dd>Take VESIcare exactly as your doctor tells you to take it. </dd>
<dt>•</dt>
<dd>You should take 1 VESIcare tablet 1 time a day.</dd>
<dt>•</dt>
<dd>You should take VESIcare with water and swallow the tablet whole.</dd>
<dt>•</dt>
<dd>You can take VESIcare with or without food.</dd>
<dt>•</dt>
<dd>If you miss a dose of VESIcare, begin taking VESIcare again the next day. Do not take 2 doses of VESIcare the same day. </dd>
<dt>•</dt>
<dd>If you take too much VESIcare, call your doctor or go to the nearest hospital emergency room right away. <br>
</dd>
</dl>
<p><br><span class="Bold">What should I avoid while taking VESIcare?</span></p>
<p>VESIcare can cause <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span> or <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>. Do not drive or operate heavy machinery until you know how VESIcare affects you.<br><br><br><span class="Bold">What are the possible side effects of VESIcare?</span></p>
<p>VESIcare may cause serious side effects including:</p>
<dl>
<dt>•</dt>
<dd>
<span class="Bold">Serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span>.</span> Stop taking VESIcare and get medical help right away if you have:<dl>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">hives</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span> or <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span></dd>
<dt>•</dt>
<dd>severe <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span></dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of your face, mouth or tongue </dd>
<dt>•</dt>
<dd>trouble breathing </dd>
</dl>
</dd>
</dl>
<p>The most common side effects of VESIcare include:</p>
<dl>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span></dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>. Call your doctor if you get severe stomach area (abdominal) <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> or become constipated for 3 or more days.</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infection</span></dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span></dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="437744" conceptname="Heat exhaustion">heat exhaustion</span> or heat-<span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>. This can happen when VESIcare is used in hot environments. Symptoms may include: <dl>
<dt>•</dt>
<dd>decreased <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span> </dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span></dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">tiredness</span></dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> </dd>
<dt>•</dt>
<dd>increase in body temperature</dd>
</dl>
</dd>
</dl>
<p>Tell your doctor if you have any side effect that bothers you or that does not go away.</p>
<p>These are not all the possible side effects of VESIcare. For more information, ask your doctor or pharmacist.</p>
<p>Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. <br><br><br><span class="Bold">How should I store VESIcare?</span></p>
<dl>
<dt>•</dt>
<dd>Store VESIcare at 59°F to 86°F (15°C to 30°C). Keep the bottle closed.</dd>
<dt>•</dt>
<dd>Safely throw away medicine that is out of date or that you no longer need.</dd>
</dl>
<p><span class="Bold">Keep VESIcare and all medicines out of the reach of children.</span><br><br><br><span class="Bold">General information about VESIcare.</span></p>
<p>Medicines are sometimes prescribed for purposes other than those listed in Patient Information leaflets. Do not use VESIcare for a condition for which it was not prescribed. Do not give VESIcare to other people, even if they have the same symptoms you have. It may harm them.</p>
<p>This leaflet summarizes the most important information about VESIcare. If you would like more information, talk with your doctor. You can ask your doctor or pharmacist for information about VESIcare that is written for health professionals. </p>
<p>For more information, go to <a href="http://www.vesicare.com/">www.vesicare.com</a> or call (800) 727-7003.<br><br><br><span class="Bold">What are the ingredients in VESIcare?</span> </p>
<p><span class="Bold">Active ingredient</span>: solifenacin succinate</p>
<p><span class="Bold">Inactive ingredients</span>: lactose monohydrate, corn starch, hypromellose 2910, magnesium stearate, talc, polyethylene glycol 8000 and titanium dioxide with yellow ferric oxide (5 mg VESIcare tablet) or red ferric oxide (10 mg VESICARE tablet)<br><br><br><span class="Bold">What is <span class="product-label-link" type="condition" conceptid="76153" conceptname="Low compliance bladder">overactive bladder</span>?</span></p>
<p><span class="product-label-link" type="condition" conceptid="76153" conceptname="Low compliance bladder">Overactive bladder</span> occurs when you cannot control your bladder contractions. When these muscle contractions happen too often or cannot be controlled you can get symptoms of <span class="product-label-link" type="condition" conceptid="76153" conceptname="Low compliance bladder">overactive bladder</span>, which are <span class="product-label-link" type="condition" conceptid="4012368" conceptname="Increased frequency of urination">urinary frequency</span>, <span class="product-label-link" type="condition" conceptid="200845" conceptname="Urgent desire to urinate">urinary urgency</span>, and <span class="product-label-link" type="condition" conceptid="197672" conceptname="Urinary incontinence">urinary incontinence</span> (leakage).<br><br><span class="Bold">Rx Only</span></p>
<p>PRODUCT OF IRELAND </p>
<p> </p>
<p>Repackaged By:</p>
<p>Cardinal Health</p>
<p>Zanesville, OH 43701</p>
<p>L78860315</p>
<p>L78850315</p>
<p>L78870815</p>
<p>L78880715<br><br>Revised: October 2013<br>13C010-VES</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="ID_e83b08e0-215d-4ea0-b317-25ce224b46a0"></a><a name="section-17"></a><p></p>
<h1>Package/Label Display Panel </h1>
<p class="First">Vesicare® 5mg</p>
<p>(Solifenacin Succinate)</p>
<p>Contains Approximately 4590 tablets</p>
<div class="Figure">
<a name="id1667127030"></a><img alt="bottle label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=5256f116-ad56-4ce0-8a5e-69d401f3ea00&amp;name=image-01.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="ID_4c87dd2d-7d05-4452-b78b-1a486ed55cc1"></a><a name="section-18"></a><p></p>
<h1>Package/Label Display Panel </h1>
<p class="First">Vesicare® 5mg</p>
<p>(Solifenacin Succinate)</p>
<p>Contains Approximately 3240 tablets</p>
<div class="Figure">
<a name="id2093586476"></a><img alt="bottle label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=5256f116-ad56-4ce0-8a5e-69d401f3ea00&amp;name=image-02.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="ID_58370aa2-7436-4810-be50-99312d7203f2"></a><a name="section-19"></a><p></p>
<h1>Package/Label Display Panel </h1>
<p class="First">Vesicare® 10mg</p>
<p>(Solifenacin Succinate)</p>
<p>Contains Approximately 4590 tablets</p>
<div class="Figure">
<a name="id-32122501"></a><img alt="bottle label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=5256f116-ad56-4ce0-8a5e-69d401f3ea00&amp;name=image-03.jpg">
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="ID_32a34704-4cfe-45ce-a30b-b6dced15b394"></a><a name="section-20"></a><p></p>
<h1>Package/Label Display Panel </h1>
<p class="First">Vesicare® 10mg</p>
<p>(Solifenacin Succinate)</p>
<p>Contains Approximately 3240 tablets</p>
<div class="Figure">
<a name="id-354580574"></a><img alt="bottle label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=5256f116-ad56-4ce0-8a5e-69d401f3ea00&amp;name=image-04.jpg">
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>VESICARE 		
					</strong><br><span class="contentTableReg">solifenacin succinate tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:55154-3877(NDC:51248-150)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>SOLIFENACIN SUCCINATE</strong> (SOLIFENACIN) </td>
<td class="formItem">SOLIFENACIN SUCCINATE</td>
<td class="formItem">5 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">yellow (YELLOW) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND (ROUND) </td>
<td class="formLabel">Size</td>
<td class="formItem">8mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">150</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:55154-3877-8</td>
<td class="formItem">4590  in 1 BOTTLE, PLASTIC; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:55154-3877-2</td>
<td class="formItem">3240  in 1 BOTTLE, PLASTIC; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA021518</td>
<td class="formItem">01/05/2005</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>VESICARE 		
					</strong><br><span class="contentTableReg">solifenacin succinate tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:55154-3878(NDC:51248-151)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>SOLIFENACIN SUCCINATE</strong> (SOLIFENACIN) </td>
<td class="formItem">SOLIFENACIN SUCCINATE</td>
<td class="formItem">10 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">pink (PINK) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND (ROUND) </td>
<td class="formLabel">Size</td>
<td class="formItem">8mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">151</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:55154-3878-8</td>
<td class="formItem">4590  in 1 BOTTLE, PLASTIC; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:55154-3878-2</td>
<td class="formItem">3240  in 1 BOTTLE, PLASTIC; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA021518</td>
<td class="formItem">01/05/2005</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Cardinal Health
							(188557102)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Cardinal Health</td>
<td class="formItem"></td>
<td class="formItem">188557102</td>
<td class="formItem">REPACK(55154-3877, 55154-3878)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 9/2015<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>c36fe294-a38b-4ccb-8c3a-b42163d79f89</div>
<div>Set id: 5256f116-ad56-4ce0-8a5e-69d401f3ea00</div>
<div>Version: 7</div>
<div>Effective Time: 20150914</div>
</div>
</div> <div class="DistributorName">Cardinal Health</div></p>
</body></html>
